03:17 AM EDT, 09/26/2024 (MT Newswires) -- Pharming Group ( PHAR ) said it has received marketing authorization in the UK for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome, a primary immunodeficiency.

The drug is currently being evaluated for potential reimbursement within England's National Health Service, the company said.